Molecular structure of Ulixertinib, CAS Number: 869886-67-9
Ulixertinib (CAS 869886-67-9)
Alternate Names:
BVD-523; VRT752271
CAS Number:
869886-67-9
Molecular Weight:
433.33
Molecular Formula:
C21H22Cl2N4O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ulixertinib (CAS 869886-67-9) References
- Determination of ulixertinib in mice plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. | Kumar, R., et al. 2016. J Pharm Biomed Anal. 125: 140-4. PMID: 27017572
- Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). | Germann, UA., et al. 2017. Mol Cancer Ther. 16: 2351-2363. PMID: 28939558
- Prediction of Human Pharmacokinetics of Ulixertinib, a Novel ERK1/2 Inhibitor from Mice, Rats, and Dogs Pharmacokinetics. | Suresh, PS., et al. 2018. Eur J Drug Metab Pharmacokinet. 43: 453-460. PMID: 29470718
- Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. | Ji, N., et al. 2018. Biochem Pharmacol. 158: 274-285. PMID: 30431011
- Pharmacokinetics and metabolism of ulixertinib in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry. | Yu, B., et al. 2020. J Sep Sci. 43: 1275-1283. PMID: 31970927
- Co-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells. | Winkler, M., et al. 2022. Transl Oncol. 16: 101313. PMID: 34906889
- The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. | Sigaud, R., et al. 2023. Neuro Oncol. 25: 566-579. PMID: 35882450
- Single-cell analysis of white adipose tissue reveals the tumor-promoting adipocyte subtypes. | Liu, SQ., et al. 2023. J Transl Med. 21: 470. PMID: 37454080
- Exosomal miR-21 determines lung-to-brain metastasis specificity through the DGKB/ERK axis within the tumor microenvironment. | Tiong, TY., et al. 2023. Life Sci. 329: 121945. PMID: 37454756
- Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells. | Chen, Y., et al. 2024. J Cancer Res Ther. 20: 570-577. PMID: 38687926
Inhibitor of:
Ankyrin-1, ErbB-3, ERK 1, ERK 2, ERRβ, Gm3696, Gm9766, KIAA1549, MAP3K3, MKP-3, MLTK, Olr307, PTOV1, SEMA3A, TFIIH p62, Vmn2r63, and ZNF264.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ulixertinib, 10 mg | sc-507296 | 10 mg | $176.00 |